| Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study N Daver, G Garcia-Manero, S Basu, PC Boddu, M Alfayez, JE Cortes, ... Cancer discovery 9 (3), 370-383, 2019 | 449 | 2019 |
| Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis I Koulouridis, M Alfayez, TA Trikalinos, EM Balk, BL Jaber American Journal of Kidney Diseases 61 (1), 44-56, 2013 | 228 | 2013 |
| CPX-351 (vyxeos) in AML M Alfayez, H Kantarjian, T Kadia, F Ravandi-Kashani, N Daver Leukemia & lymphoma 61 (2), 288-297, 2020 | 85 | 2020 |
| Gut microbiome signatures are predictive of infectious risk following induction therapy for acute myeloid leukemia JR Galloway-Peña, Y Shi, CB Peterson, P Sahasrabhojane, ... Clinical Infectious Diseases 71 (1), 63-71, 2020 | 71 | 2020 |
| Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study I Koulouridis, M Alfayez, H Tighiouart, NE Madias, DM Kent, JK Paulus, ... American journal of kidney diseases 62 (4), 730-737, 2013 | 71 | 2013 |
| Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes PC Boddu, TM Kadia, G Garcia‐Manero, J Cortes, M Alfayez, G Borthakur, ... Cancer 125 (7), 1091-1100, 2019 | 67 | 2019 |
| Azacitidine (AZA) with nivolumab (Nivo), and AZA with Nivo+ ipilimumab (Ipi) in relapsed/refractory acute myeloid leukemia: a non-randomized, prospective, phase 2 study NG Daver, G Garcia-Manero, MY Konopleva, M Alfayez, N Pemmaraju, ... Blood 134, 830, 2019 | 52 | 2019 |
| The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia M Alfayez, GC Issa, KP Patel, F Wang, X Wang, NJ Short, JE Cortes, ... Leukemia 35 (3), 691-700, 2021 | 51 | 2021 |
| Therapeutic hypothermia and prevention of acute kidney injury: a meta-analysis of randomized controlled trials P Susantitaphong, M Alfayez, A Cohen-Bucay, EM Balk, BL Jaber Resuscitation 83 (2), 159-167, 2012 | 50 | 2012 |
| Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors B Oran, G Garcia‐Manero, RM Saliba, M Alfayez, G Al‐Atrash, SO Ciurea, ... Cancer 126 (10), 2193-2205, 2020 | 41 | 2020 |
| Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors HT Chifotides, L Masarova, M Alfayez, N Daver, Y Alvarado, E Jabbour, ... Blood advances 4 (21), 5336-5342, 2020 | 40 | 2020 |
| Midostaurin in acute myeloid leukemia: an evidence-based review and patient selection HA Abbas, M Alfayez, T Kadia, F Ravandi-Kashani, N Daver Cancer management and research, 8817-8828, 2019 | 35 | 2019 |
| Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN) HC Beird, M Khan, F Wang, M Alfayez, T Cai, L Zhao, J Khoury, ... Blood cancer journal 9 (12), 99, 2019 | 34 | 2019 |
| First report of clinical response to venetoclax in early T-cell precursor acute lymphoblastic leukemia Y Numan, M Alfayez, A Maiti, Y Alvarado, EJ Jabbour, A Ferrajoli, ... JCO precision oncology 2, 2018 | 33 | 2018 |
| Sudden blastic transformation in treatment‐free remission chronic myeloid leukaemia. M Alfayez, G Richard‐Carpentier, E Jabbour, P Vishnu, K Naqvi, K Sasaki, ... British Journal of Haematology 187 (4), 2019 | 27 | 2019 |
| Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges M Alfayez, G Borthakur Expert review of hematology 11 (5), 373-389, 2018 | 26 | 2018 |
| Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype M Alfayez, SA Wang, SA Bannon, DP Kontoyiannis, SM Kornblau, ... Leukemia & Lymphoma 60 (8), 2025-2033, 2019 | 21 | 2019 |
| Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML M Yilmaz, M Alfayez, CD DiNardo, G Borthakur, TM Kadia, MY Konopleva, ... Journal of hematology & oncology 13, 1-12, 2020 | 20 | 2020 |
| New concepts of treatment for patients with myelofibrosis P Bose, M Alfayez, S Verstovsek Current treatment options in oncology 20, 1-25, 2019 | 19 | 2019 |
| Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy HA Abbas, Z Alaniz, S Mackay, M Cyr, J Zhou, GC Issa, M Alfayez, ... Blood Advances 5 (22), 4569-4574, 2021 | 17 | 2021 |
